Vanda Pharmaceuticals (VNDA) Receivables (2010 - 2026)

Vanda Pharmaceuticals has reported Receivables for 17 years, with the latest figure at $56.9 million in Q1 2026.

• Quarterly Receivables rose 27.52% year-over-year to $56.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.9 million (up 27.52% YoY) and the FY2025 annual result came in at $54.6 million, up 15.87% from the prior year.
• Receivables improved to $56.9 million in Q1 2026 per VNDA's latest filing, from $54.6 million in the prior quarter.
• Over five years, Receivables peaked at $56.9 million in Q1 2026 and troughed at $24.5 million in Q1 2023.
• A 5-year average of $39.0 million and a median of $36.7 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2024: Receivables fell 29.27% in 2022, then surged 49.77% in 2024.
• Over 5 years, Receivables stood at $33.5 million in 2022, then advanced by 1.92% to $34.2 million in 2023, then surged by 37.9% to $47.1 million in 2024, then gained by 15.87% to $54.6 million in 2025, then rose by 4.22% to $56.9 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $56.9 million, $54.6 million, and $50.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.